• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Akebia Therapeutics (NQ: AKBA )

    1.690 +0.030 (+1.81%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Akebia Therapeutics

    < Previous 1 2 3 4 5 6 Next >
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Gainers Oncternal Therapeutics (NASDAQ:ONCT 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) stock moved upwards by 20.4% to $1.06 during Thursday's pre-market session. The market value of their outstanding shares is... 
    Via Benzinga
    Akebia Therapeutics, inc (AKBA) Q3 2021 Earnings Call Transcript
    AKBA earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
    The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... 
    Via Benzinga
    Exposures Product Safety
    99 Biggest Movers From Yesterday
    Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
    Via Benzinga
    Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript
    AKBA earnings call for the period ending June 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Why Akebia Therapeutics Stock Is Soaring Today
    Investors liked what they heard in the company's Q2 update. 
    Via The Motley Fool
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger
    From Robbins LLP
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers Akebia Therapeutics (NASDAQ:AKBA... 
    Via Benzinga
    Akebia Therapeutics Insights: Return On Capital Employed
    During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. In Q4, Akebia... 
    Via Benzinga
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Cramer Gives His Opinion On Novavax, Exact Sciences And More
    On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers Moderna Inc (NASDAQ: MRNA) over Novavax, Inc. (NASDAQ: NVAX). Philip Morris International Inc. (... 
    Via Benzinga
    Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise
    Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the... 
    Via Benzinga
    Looking Into Akebia Therapeutics's Return On Capital Employed
    During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. Akebia... 
    Via Benzinga
    Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
    Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat... 
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Gainers Paratek Pharmaceuticals (NASDAQ:PRTK) stock increased by 12.65% to $9.26 during Tuesday's pre-market session. The company's market cap stands at $434.5... 
    Via Benzinga
    Akebia Therapeutics, Inc. (NASDAQ: AKBA) Investor Alert: Investigation over Potential Wrongdoing
    San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares over potential wrongdoing at Akebia Therapeutics, Inc was announced... 
    Via SBWire
    Recap: Akebia Therapeutics Q1 Earnings
    Shares of Akebia Therapeutics (NASDAQ:AKBA) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 4.26% year over... 
    Via Benzinga
    The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
    Via Benzinga
    The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
    Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    28 Stocks Moving in Thursday's Pre-Market Session
    Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 39.6% to $9.23 in pre-market trading after the company disclosed updated data from its randomized, multicenter, placebo-... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.